Valeant Pharmaceuticals

4 pages

Finance Valeant Shareholders Push for More Details About CEO’s Illness
BYReuters
March 14, 2016
Features Fed Meeting, Valeant Earnings, and March Madness—5 Things to Know for the Week Ahead
BYTom Huddleston Jr.
March 13, 2016
Health Bill Ackman Just Got Himself a Board Member on Valeant
BYReuters
March 9, 2016
Finance Here’s Why Shares of Valeant Are Jumping Today
BYReuters
March 7, 2016
Finance This Is Why Hillary Clinton’s Attack on Drug Price Hikes Doesn’t Add Up
BYJen Wieczner
March 4, 2016
Finance Valeant Is Being Investigated by the SEC and Shares Are Plunging
BYDan Primack
February 29, 2016

Finance This Is Why Shares of Valeant Are Cratering Today
BYLucinda Shen
February 29, 2016
Finance Why Valeant’s Stock Surged After CEO Admitted ‘Mistakes’
BYJen Wieczner
February 23, 2016
Health Study Says This Cold Medicine Doesn’t Actually Fight Colds
BYMichal Addady
February 1, 2016
Finance These Stock Market-Battered Execs Just Became Ex-Billionaires
BYRobert Hackett
January 26, 2016
Health Doomsday Postponed and Valeant’s Management Talks–5 Things to Know Today
BYLaura Lorenzetti and Geoffrey Smith
January 13, 2016
Finance Valeant CEO Says Board Is ‘Welcome to Fire Me’
BYJen Wieczner
December 16, 2015
Finance Congressman Calls Out Valeant’s ‘Lack of Transparency’
BYLaura Lorenzetti
December 16, 2015
Finance Novartis Agrees to $390 Million Settlement
BYJen Wieczner
November 20, 2015
Retail Why the drug price scandal won’t be enough to keep down prices
BYLaura Lorenzetti
October 26, 2015

Most Popular

31 - 45 of 60 results